阿尔茨海默病免疫治疗新进展及其药物研发展望

摘要

The main pathological signature of Alzheimer disease ( AD ) is characterized by β amyloid deposits in the form of extracellular amyloid β ( Aβ) plaques and tau protein aggregates in the form of intracellular neurofibrillary tangles ( NFT ) . An exciting new approach to treat AD is the immunization approach. Immunotherapeutic agents mainly include nonsteroidal anti-inflammatory drugs ( NSAID ) , pas-sive and active immunization. Recent studies have indicated that AD clinical progress can't be slowed only by cleaning Aβ, and the current main development direction is the immunotherapy targeting tau protein. More and more researchers and pharmaceutical companies start paying attention to AD immunotherapy. Although facing great challenge, huge economic and social returns will be delivered by suc-ceeding in AD drug development.%阿尔茨海默病( AD )的主要病理特征是脑内β淀粉样蛋白( Aβ)沉积形成的老年斑和tau聚集形成的神经纤维缠结。AD免疫疗法是这一领域中的新突破，免疫治疗药物主要包括非甾体抗炎药、主动和被动免疫治疗药物。目前的研究表明，仅清除Aβ并不能阻止AD的进展，而直接以tau蛋白为靶点的免疫治疗策略是目前的重要研究方向。已经有越来越多的研究者和医药企业开始关注AD的免疫疗法，虽面临巨大挑战，但获得这一领域药物研发的成功，无疑将会产生巨大的经济和社会效益。